{
    "nctId": "NCT05267327",
    "briefTitle": "A Prospective Post-Marketing Observational Safety Study of Verzenios\u00ae (Abemaciclib) Among Breast Cancer Patients in China Verzenios\u00ae (Abemaciclib) Among Breast",
    "officialTitle": "A Prospective Post-Marketing Observational Safety Study of Verzenios\u00ae (Abemaciclib) Among Breast Cancer Patients in China",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "The Incidence of AEs and SAEs Receiving Verzenios\u00ae Over a Period of Approximately 24 Weeks",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1500,
    "primaryOutcomeMeasure": "The Incidence of AEs and SAEs",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* at least 18 years old at enrolment\n* diagnosed with HR-positive, HER2-negative breast cancer\n* prescribed with Verzenios by the investigators and started (or planned to start shortly) Verzenios treatment in the routine care of the patient\n* provide written consent to the release of their data after being informed of the study.\n\nExclusion Criteria:\n\n* have been administered Verzenios before study enrollment\n* are simultaneously participating in a different study that includes a treatment intervention and/or an investigational drug\n* are pregnant or breastfeeding or intend to become pregnant within the duration of the study\n* contraindicated for the use of Verzenios according to the China approved label.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}